(Q36766032)

16 August 2017

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors (English)

1 reference

16 August 2017

phase I clinical trial

0 references

1 reference

1 reference

3

Hardev S Pandha

1 reference

16 August 2017

10

Johann de Bono

1 reference

16 August 2017

Victoria Roulstone

1

1 reference

16 August 2017

Khurum Khan

2

1 reference

16 August 2017

Sarah Rudman

4

1 reference

16 August 2017

Matt Coffey

5

1 reference

16 August 2017

George M Gill

6

1 reference

16 August 2017

Alan A Melcher

7

1 reference

16 August 2017

Richard Vile

8

1 reference

16 August 2017

Kevin J Harrington

9

1 reference

16 August 2017

James Spicer

11

1 reference

16 August 2017

language of work or name

English

0 references

publication date

25 November 2014

1 reference

16 August 2017

Clinical Cancer Research

1 reference

16 August 2017

21

1 reference

16 August 2017

6

1 reference

16 August 2017

1305-1312

1 reference

Oncolytic virotherapy needs trials, not access programs

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

ras oncogenes in human cancer: a review

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

The virus that came in from the cold

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Reovirus infections in human volunteers.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4821068

Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1

20 October 2018

1 reference

12 December 2020

Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma

1 reference

12 December 2020

Reovirus type 3 chemoimmunotherapy of murine lymphoma is abrogated by cyclosporine

1 reference

12 December 2020

Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described

1 reference

12 December 2020

10.1158/1078-0432.CCR-14-1770

Identifiers

DOI

1 reference

10.1158/1078-0432.CCR-14-1770

16 August 2017

0 references

Dimensions Publication ID

0 references

1 reference

16 August 2017

1 reference